Watch our latest investor update
![pharmaus 210 pharmaus 210](https://www.pharmaust.com/wp-content/uploads/2017/11/pharmaus-210-2-419x285.jpg)
OUR COMPANY
PharmAust is a clinical-stage biotechnology company developing new therapeutics for human and animal health applications. The company is repurposing monepantel for the treatment of cancer in dogs and neurodegenerative diseases in humans.
![pharmaust research pharmaust research](https://www.pharmaust.com/wp-content/uploads/2017/03/pharmaust-research-419x285.jpg)
OUR SCIENCE
Monepantel is an approved veterinary product for the treatment of nematode infestations in sheep. In mammalian cells, monepantel is a potent inhibitor of the mTOR pathway. The mTOR pathway plays a central role in cell growth and proliferation of cancer cells.